Chong Kun Dang announced on the 9th that its type 2 diabetes treatment drug, Dubies Jeong (active ingredients: lobeglitazone sulfate and sitagliptin), has received domestic product approval from the Ministry of Food and Drug Safety.
Dubies Jeong can be used for adult patients with type 2 diabetes who are suitable for combination therapy with lobeglitazone and sitagliptin. Dubies Jeong is scheduled to be launched in the domestic market in September.
Chong Kun Dang stated that Dubies Jeong is expected to provide a new treatment option for type 2 diabetes patients whose blood sugar is not controlled by combination therapy with sitagliptin and metformin, and to improve medication convenience.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
